28 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships.
University of T£Bingen
Novel toll-like receptor 2 ligands for targeted pancreatic cancer imaging and immunotherapy.
H. Lee Moffitt Cancer Center and Research Institute
Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.
University of Kansas
Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.
University of Kansas
Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides.
University of Kansas
Identification and immunological evaluation of novel TLR2 agonists through structural optimization of Diprovocim.
Fudan University
Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics.
West China Hospital
TLR2 Agonistic Small Molecules: Detailed Structure-Activity Relationship, Applications, and Future Prospects.
Panjab University
Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune Response.
The Scripps Research Institute
Toll-like receptor 2 antagonists. Part 1: preliminary SAR investigation of novel synthetic phospholipids.
Eisai Research Institute
Design and optimisation of a small-molecule TLR2/4 antagonist for anti-tumour therapy.
Tsinghua University
Structure based design and synthesis of novel Toll-like Receptor 2 (TLR 2) lipid antagonists.
Neuropore Therapies
Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles.
University of Kansas
Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists.
University of Siena
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.
Genomics Institute of The Novartis Research Foundation
Identification and immunological evaluation of novel TLR2 agonists through structure optimization of Pam
Fudan University
Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines.
University of Auckland
Structure-activity relationship study and biological evaluation of SAC-Garlic acid conjugates as novel anti-inflammatory agents.
Southern Medical University
Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim.
University of Pittsburgh
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[
Glaxosmithkline
Synthesis of urea analogues bearing N-alkyl-N'-(thiophen-2-yl) scaffold and evaluation of their innate immune response to toll-like receptors.
Southern Medical University
Identification of Human Toll-like Receptor 2-Agonistic Activity in Dihydropyridine-Quinolone Carboxamides.
University of Minnesota
Site-specific effect of polar functional group-modification in lipids of TLR2 ligands for modulating the ligand immunostimulatory activity.
Keio University
Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.
University of Colorado Boulder
